CoRegen – a biopharmaceutical company developing new treatments for aggressive cancers – announced it has successfully closed a $93.39 million financing round. This funding round will advance the company’s chemistry, manufacturing, and controls (CMC) development and enable the initiation of a Phase 1/2 clinical trial in the first half of 2026.
The trial will focus on its steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO) program for various solid tumor types. The investment will also support the expansion of CoRegen’s leadership team.
This funding builds on a previous $28 million raise in early 2024, which secured an exclusive license from Baylor College of Medicine for its innovative gene regulatory platform. CoRegen’s platform is based on the work of Dr. Bert O’Malley, focusing on SRC-3, which is overexpressed in most human cancers and crucial for Treg cell cancer protection.
By engineering cells with SRC-3 knocked out, CoRegen aims to target a broad network of immune checkpoint genes for a superior anti-tumor effect.
KEY QUOTE:
“We are delighted to have the support of our investors during this pivotal time of growth for the company. This year marks a watershed moment as we build upon the tremendous scientific progress made by Dr. Bert O’Malley and his team at the Baylor College of Medicine. As we prepare to enter the clinic, we are motivated by the belief we have a potentially paradigm-shifting solution in our master gene regulatory platform for patients with some of the most difficult-to-treat solid-tumor cancers, including but not limited to triple negative breast cancer and glioblastoma, for which research to date hasn’t yet moved the needle in a meaningful way in many years. We believe our technology, a type of adoptive cell therapy (ACT), may provide a novel approach for unleashing the healing power of the immune system to eradicate additional forms of cancer.”
Suneet Varma, CoRegen’s newly appointed Chairman
